Y-mAbs Therapeutics, Inc. (YMAB) SEC filings
YMAB SEC filings moved a median of -0.52% by the close. YMAB SEC filings — 10-K, 10-Q, 8-K and the rest — each read against the price at its own news timestamp. Back to the YMAB overview →
46 measured YMAB SEC filing events.
Where these YMAB SEC filings landedvs 41 measured YMAB SEC filing reactions
| Middle 50% of YMAB SEC filing reactions | -4.97% to +2.35% |
|---|---|
| Median reaction (to close) | -0.52% |
| Measured reactions | 41 |
Point-in-time · zero look-ahead
Half of the 41 YMAB SEC filing events with a measured close landed between -4.97% and +2.35%; 34% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 15-12G Y-mAbs Therapeutics, | SEC filing · Form 15-12G | — | — | |
| Form EFFECT Y-mAbs Therapeutics, | SEC filing · Form EFFECT | — | — | |
| Form 8-K Y-mAbs Therapeutics, For: Sep 16 | SEC filing · Form 8-K | — | — | |
| Form POS AM Y-mAbs Therapeutics, | SEC filing · Form POS | — | — | |
| Form S-8 POS Y-mAbs Therapeutics, | SEC filing · Form S-8 | — | — | |
| Form 10-Q Y-mAbs Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.06% | +0.00% | |
| Form 8-K Y-mAbs Therapeutics, For: Aug 08 | SEC filing · Form 8-K | -0.06% | +0.00% | |
| Form 8-K Y-mAbs Therapeutics, For: Aug 04 | SEC filing · Form 8-K | +0.12% | +0.00% | |
| Form 8-K Y-mAbs Therapeutics, For: Jul 11 | SEC filing · Form 8-K | -1.18% | +2.35% | |
| Form ARS Y-mAbs Therapeutics, For: Dec 31 | SEC filing · Form ARS | +0.18% | +4.18% | |
| Form DEF 14A Y-mAbs Therapeutics, For: Jul 11 | SEC filing · Form DEF | +0.18% | +4.18% | |
| Form DEFA14A Y-mAbs Therapeutics, | SEC filing · Form DEFA14A | +0.18% | +4.18% | |
| Form 8-K Y-mAbs Therapeutics, For: May 28 | SEC filing · Form 8-K | +0.91% | +4.53% | |
| Form 10-Q Y-mAbs Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +6.70% | -7.14% | |
| Form 8-K Y-mAbs Therapeutics, For: May 13 | SEC filing · Form 8-K | +6.70% | -7.14% | |
| Form 10-K/A Y-mAbs Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.90% | -0.47% | |
| Form 10-K Y-mAbs Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +1.14% | +13.24% | |
| Form 8-K Y-mAbs Therapeutics, For: Mar 04 | SEC filing · Form 8-K | +1.14% | +13.24% | |
| Form S-8 Y-mAbs Therapeutics, | SEC filing · Form S-8 | +1.14% | +13.24% | |
| Form 8-K Y-mAbs Therapeutics, For: Jan 13 | SEC filing · Form 8-K | -2.63% | -4.97% | |
| Form 8-K Y-mAbs Therapeutics, For: Jan 06 | SEC filing · Form 8-K | -0.35% | -4.70% | |
| Form 10-Q Y-mAbs Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -7.46% | +12.17% | |
| Form 8-K Y-mAbs Therapeutics, For: Nov 08 | SEC filing · Form 8-K | -7.46% | +12.17% | |
| Form 8-K Y-mAbs Therapeutics, For: Oct 29 | SEC filing · Form 8-K | -0.14% | +2.27% | |
| Form 8-K Y-mAbs Therapeutics, For: Sep 17 | SEC filing · Form 8-K | -0.43% | -5.91% | |
| Form 8-K Y-mAbs Therapeutics, For: Sep 11 | SEC filing · Form 8-K | -0.42% | -4.77% | |
| Form 10-Q Y-mAbs Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -10.75% | +0.91% | |
| Form 8-K Y-mAbs Therapeutics, For: Aug 12 | SEC filing · Form 8-K | -10.75% | +0.91% | |
| Form 8-K Y-mAbs Therapeutics, For: Jul 16 | SEC filing · Form 8-K | +0.00% | +4.65% | |
| Form 8-K Y-mAbs Therapeutics, For: Jun 27 | SEC filing · Form 8-K | -1.24% | -2.49% | |
| Form 8-K Y-mAbs Therapeutics, For: Jun 26 | SEC filing · Form 8-K | +1.67% | -1.50% | |
| Form 8-K Y-mAbs Therapeutics, For: Jun 11 | SEC filing · Form 8-K | -0.34% | -0.25% | |
| Form 10-Q Y-mAbs Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -1.16% | -12.42% | |
| Form 8-K Y-mAbs Therapeutics, For: May 07 | SEC filing · Form 8-K | -1.16% | -12.42% | |
| Form 8-K Y-mAbs Therapeutics, For: Apr 25 | SEC filing · Form 8-K | -0.59% | -0.52% | |
| Form ARS Y-mAbs Therapeutics, For: Dec 31 | SEC filing · Form ARS | -0.59% | -0.52% | |
| Form DEF 14A Y-mAbs Therapeutics, For: Jun 11 | SEC filing · Form DEF | -0.59% | -0.52% | |
| Form DEFA14A Y-mAbs Therapeutics, | SEC filing · Form DEFA14A | -0.59% | -0.52% | |
| Form 8-K Y-mAbs Therapeutics, For: Mar 08 | SEC filing · Form 8-K | +1.71% | -1.32% | |
| Form 8-K Y-mAbs Therapeutics, For: Feb 29 | SEC filing · Form 8-K | -2.15% | -6.83% | |
| Form 10-K Y-mAbs Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -4.73% | -8.52% | |
| Form 8-K Y-mAbs Therapeutics, For: Feb 29 | SEC filing · Form 8-K | -4.73% | -8.52% | |
| Form S-8 Y-mAbs Therapeutics, | SEC filing · Form S-8 | -4.73% | -8.52% | |
| Form 8-K Y-mAbs Therapeutics, For: Jan 08 | SEC filing · Form 8-K | -3.51% | -6.50% | |
| Form 10-Q Y-mAbs Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.99% | -3.07% | |
| Form 8-K Y-mAbs Therapeutics, For: Nov 13 | SEC filing · Form 8-K | -1.99% | -3.07% |
Keep exploring
More YMAB: earnings → · analyst actions → · YMAB overview →
Other Healthcare names and their SEC filings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GSRX INDUSTRIES INC (GSRX) | 226 | 0.00% | 19% |
| TETRALOGIC PHARMS CORP (TLOG) | 226 | +0.20% | 52% |
| Aurinia Pharmaceuticals Inc - Common Shares (AUPH) | 224 | +0.13% | 54% |
| Cel-Sci Corporation (CVM) | 224 | -0.54% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its SEC filings — that is what the link opens.